Beyond the Guidelines: Perspectives on the Role of PARP Inhibition in the Management of Ovarian Cancer

Listen to streaming audioright from your computer
Download the programto your desktop
Subscribe to podcastto have this and future issues delivered to your iTunes library

Audio Highlights

Topic 1:	Genomic testing for patients with newly diagnosed ovarian cancer (OC)
Topic 2:	Management of OC with germline BRCA mutation after surgical debulking; role of bevacizumab and PARP inhibitors
Topic 3:	Therapeutic approach for patients with homologous recombination-proficient OC
Topic 4:	Molecular profiling and genetic counseling for patients with newly diagnosed OC
Topic 5:	FDA approval and optimal use of niraparib or olaparib/bevacizumab as front-line maintenance therapy for patients with advanced OC
Topic 6:	Perspective on the benefit with bevacizumab and a PARP inhibitor for patients with OC
Topic 7:	Clinical implications of the Phase III VELIA study assessing veliparib in combination with carboplatin/paclitaxel and as continuation maintenance therapy for newly diagnosed advanced OC
Topic 8:	Homologous recombination deficiency testing and implications for treatment decision-making in newly diagnosed advanced OC
Topic 9:	Risks with combining PARP inhibitor therapy and chemotherapy for advanced OC; optimizing the use of chemotherapy, bevacizumab and a PARP inhibitor in the front-line setting
Topic 10:	Overall survival data with maintenance olaparib for platinum-sensitive recurrent OC with germline BRCA mutation from the Phase III SOLO-2 trial; optimal integration of PARP inhibitors in the treatment of recurrent disease

FACULTY

Robert L Coleman, MD
Chief Scientific Officer
US Oncology Research
Gynecologic Oncology
McKesson
The Woodlands, Texas

Stephanie Lheureux, MD, PhD
Clinician Investigator
Drug Development Program - Gynecology
Division of Medical Oncology and Hematology
Gynecology Site Lead
Princess Margaret Cancer Centre
Assistant Professor
University of Toronto
Toronto, Canada

Joyce F Liu, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Director of Clinical Research, Division of Gynecologic Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Kathleen Moore, MD
The Virginia Kerley Cade Endowed Chair in Cancer Development
Associate Director
Clinical Research
Director
Oklahoma TSET Phase I Program
Stephenson Cancer Center
Associate Professor
Section of Gynecologic Oncology
Director
Gynecologic Oncology Fellowship
Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

EDITOR

Neil Love, MD
Research To Practice
Miami, Florida